Contracts › 75N93022C00058
75N93022C00058: Development of an Intranasal Vaccine Against Gonorrhea Based on Outer Membrane Vesicles Combined With Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.
Awarded to Intravacc B.V. by National Institutes of Health (NIH).
$6.6Mobligated
$14.6Mpotential value
30 December 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93022C00058 |
|---|---|
| Awardee | Intravacc B.V. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Offers received | 10 |
| Period of performance | 21 September 2022 to 30 December 2026 |
| Potential end | 30 December 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record